Zacks Research Weighs in on Exelixis, Inc.’s Q2 2025 Earnings (NASDAQ:EXEL)

Exelixis, Inc. (NASDAQ:EXEL) – Equities research analysts at Zacks Research reduced their Q2 2025 earnings per share estimates for shares of Exelixis in a report issued on Monday, September 16th. Zacks Research analyst E. Bagri now forecasts that the biotechnology company will post earnings of $0.34 per share for the quarter, down from their previous estimate of $0.37. The consensus estimate for Exelixis’ current full-year earnings is $1.54 per share. Zacks Research also issued estimates for Exelixis’ Q3 2025 earnings at $0.34 EPS and Q1 2026 earnings at $0.39 EPS.

Several other research firms have also issued reports on EXEL. JMP Securities reiterated a “market outperform” rating and set a $29.00 target price on shares of Exelixis in a report on Friday. Truist Financial restated a “buy” rating and set a $33.00 target price (up from $32.00) on shares of Exelixis in a report on Thursday, August 8th. UBS Group started coverage on shares of Exelixis in a research note on Thursday. They issued a “neutral” rating and a $30.00 price target for the company. Oppenheimer reissued an “outperform” rating and issued a $29.00 price objective on shares of Exelixis in a research report on Tuesday, July 30th. Finally, StockNews.com raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 13th. Five investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Exelixis presently has a consensus rating of “Moderate Buy” and an average target price of $27.67.

Exelixis Stock Performance

NASDAQ EXEL opened at $26.42 on Thursday. Exelixis has a 52 week low of $18.64 and a 52 week high of $27.83. The stock has a market capitalization of $8.01 billion, a price-to-earnings ratio of 41.28, a PEG ratio of 0.58 and a beta of 0.54. The stock’s 50 day moving average price is $25.12 and its two-hundred day moving average price is $23.31.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.44. Exelixis had a net margin of 17.38% and a return on equity of 15.54%. The company had revenue of $637.18 million during the quarter, compared to analysts’ expectations of $468.21 million.

Hedge Funds Weigh In On Exelixis

Several large investors have recently bought and sold shares of EXEL. Sanctuary Advisors LLC acquired a new position in Exelixis in the 2nd quarter valued at approximately $652,000. Creative Planning increased its stake in shares of Exelixis by 0.8% in the second quarter. Creative Planning now owns 71,700 shares of the biotechnology company’s stock valued at $1,611,000 after buying an additional 548 shares during the period. Algert Global LLC raised its position in shares of Exelixis by 7.6% during the second quarter. Algert Global LLC now owns 276,352 shares of the biotechnology company’s stock worth $6,210,000 after acquiring an additional 19,559 shares during the last quarter. Mackenzie Financial Corp boosted its holdings in Exelixis by 62.1% in the second quarter. Mackenzie Financial Corp now owns 433,311 shares of the biotechnology company’s stock valued at $9,736,000 after acquiring an additional 166,057 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C increased its position in Exelixis by 137.1% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 20,816 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 12,036 shares during the period. 85.27% of the stock is currently owned by institutional investors.

Insider Activity

In other Exelixis news, Director Maria C. Freire sold 8,250 shares of the firm’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $26.56, for a total transaction of $219,120.00. Following the transaction, the director now owns 91,007 shares in the company, valued at approximately $2,417,145.92. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, Director Maria C. Freire sold 8,250 shares of Exelixis stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $26.56, for a total value of $219,120.00. Following the transaction, the director now owns 91,007 shares in the company, valued at approximately $2,417,145.92. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Christopher J. Senner sold 125,000 shares of the company’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $27.19, for a total value of $3,398,750.00. Following the sale, the chief financial officer now owns 721,680 shares of the company’s stock, valued at $19,622,479.20. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 302,858 shares of company stock worth $7,980,629. Corporate insiders own 2.85% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.